EU/3/09/666

Table of contents

About

On 8 October 2009, orphan designation (EU/3/09/666) was granted by the European Commission to S.L.A. Pharma (UK) Ltd, United Kingdom, for eicosapentaenoic acid for the treatment of familial adenomatous polyposis.

The sponsor’s address was updated in March 2021.

The sponsorship was transferred to SLA Pharma (IRE) Limited, Ireland, in April 2021.

Key facts

Active substance
Eicosapentaenoic acid
Disease / condition
Treatment of familial adenomatous polyposis (FAP)
Date of first decision
08/10/2009
Outcome
Positive
EU designation number
EU/3/09/666

Sponsor's contact details

SLA Pharma (IRE) Limited
Unit 3d North Point House
North Point Business Park
New Mallow Road
Cork
Ireland
Email: admin@slapharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating